Work Here?
Overview
Abiologics develops a new class of programmable medicines called supranatural biologics to treat a wide range of diseases. By combining artificial intelligence with chemistry, the company designs these therapeutics to be more precise and effective than traditional treatments. Unlike many biotech firms that focus on a single drug, Abiologics uses a multidisciplinary platform to build a toolkit of proprietary biologics that it licenses to pharmaceutical partners. The company's goal is to systematically expand the possibilities of modern medicine by creating a scalable library of programmable treatments for healthcare providers.
About Abiologics
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Early VC
Total Funding
$50M
Headquarters
Cambridge, Massachusetts
Founded
2020
Your Connections
People at Abiologics who can refer or advise you
Simplify's Take
What believers are saying
- Maria-Chiara Magnone joins as CSO from J&J with cardiovascular and metabolic disease expertise.
- Initial $50M from Flagship Pioneering funds oncology and immunology pipeline development.
- Synteins address fundamental limitations of traditional biologics: protease resistance and immune evasion.
What critics are saying
- Generate Biomedicines and Absci advance competing AI-designed protein platforms with faster clinical progression.
- FDA scrutiny on AI-generated biologics may halt IND filings for D-amino acid Synteins.
- Synthesis instability of non-natural amino acids threatens platform viability at scale-up stage.
What makes Abiologics unique
- D-amino acid Synteins evade immune defenses while binding diverse therapeutic targets.
- Fully integrated digital and automated wet-lab infrastructure enables rapid Syntein design and synthesis.
- Generative AI computationally designs biologics using artificial building blocks beyond natural amino acids.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$50M
Above
Industry Average
Funded Over
1 Rounds
Benefits
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -9%1 year growth
↓ -9%2 year growth
↓ -4%Magnone joins Abiologics from Johnson & Johnson (J&J), where she was initially Vice President, Kidney Disease Research and Boston Site Head, and more recently Vice President, Head of Discovery for the Cardiovascular, Metabolic, Retina and Pulmonary Hypertension therapeutic area.
He spoke of how UMass Boston is collaborating with Abiologics, the newest of the three Flagship companies operating out of South Line, sharing specialized equipment along with expertise.
The Abiologics platform leverages cutting-edge generative AI and high throughput chemical protein synthesis to create Synteins™, a new class of programmable medicines that aims to redefine what therapeutics can achieve for patientsThe company emerges after 3 years of platform development and an initial commitment of $50 million from Flagship PioneeringCAMBRIDGE, Mass., July 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Abiologics, a company reimagining biologics with the creation of a new class of supranatural and programmable medicines, called Synteins™. Synteins are computationally-generated and synthesized with novel building blocks, endowing them with extraordinary properties to bring life-changing treatments to patients across a wide range of diseases. Flagship has initially committed $50 million to advance the company's platform and develop a diverse pipeline of medicines, with an initial focus on oncology and immunology indications.Abiologics"Biologics have transformed medicine in the past forty years, but only a fraction of their potential has been realized because we've been limited by the boundaries of nature," said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder and Chairman of the Strategic Oversight Board of Abiologics. "With the convergence of advancements in generative artificial intelligence, automated polymer synthesis and chemical functionalization coupled with a vision to develop more powerful medicines with unprecedented diversity, we asked, what if we could design biologics entirely from new building blocks that could overcome the most critical limitations of today's medicines?"The Abiologics platform is a fully integrated digital and automated wet-lab infrastructure to create supranatural biologics with powerful, desirable pharmacological properties. The platform leverages state-of-the-art generative artificial intelligence (AI) to computationally-design Synteins de novo using a broad set of artificial building blocks, far beyond the 20 naturally occurring amino acids that form the basis of today's biologic medicines. These include biologics built with D-amino acids, chemically identical mirror images of standard amino acids
Abiologics is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Abiologics
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Early VC
Total Funding
$50M
Headquarters
Cambridge, Massachusetts
Founded
2020
Abiologics is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today